AEGiS-GMHC: IN BRIEF: More Data On Low-Dose AZT

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

IN BRIEF: More Data On Low-Dose AZT

Gay Men's Health Crisis Treatment Issues, Vol. 5, No. 5 - June 20, 1991
David Barr

Preliminary data from a European trial comparing AZT at doses of 1200 mg versus 600 mg in 76 persons with AIDS or ARC were reported in an early May edition of Lancet. These data underscore U. S. findings, which now recommend 600 mg of AZT daily. The European study found that 46% of patients in the full-dose group and in 44% of patients in the half-dose group progressed to AIDS, demonstrating equal efficacy for both doses. Survival rates and differences in T4 counts and p24 antigen measurements were not observed between the two groups. The 600 mg regimen was also better tolerated. These results are further proof that 600 mg AZT/day should now be considered "full dose." However, some physicians feel that higher doses are more effective for lymphoma and HIV-related neurological problems.

Copyright (c) 1991 - Gay Men's Health Crisis, Inc. All rights reserved. Non-commercial reproduction is encouraged. Distributed by AEGIS, your online gateway to a world of people, knowledge, and resources. Direct Dial: v.34+: 714.248.2836; v.120/ISDN: 714.248.0433 Internet: telnet:aegis.com www: www.aegis.com

910620
GM050504

Copyright © 1991 - Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, Inc. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 fredg@gmhc.org http://www.gmhc.org

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .